Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ana Pimentel

Podiatrist Hackensack, NJ Doctor of Podiatric Medicine

NPI 1528516663 CMS profile 2779473

25 Prospect Ave, Hackensack, NJ 07601

Open in the dashboard

General payments

$12,258

107 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ana Pimentel of Hackensack, NJ is reported in the CMS Open Payments database as having received $12,258 across 107 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,015 24
2024 General $1,262 15
2023 General $4,369 28
2022 General $1,774 9
2021 General $277 5
2020 General $1,423 17
2019 General $1,139 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ana Pimentel
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Ana Pimentel were reported at $2,015. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Ana Pimentel Podiatrist median Middle half National median
2019 $1,139 $196 $72–$601 $163
2020 $1,423 $118 $38–$335 $114
2021 $277 $169 $57–$573 $132
2022 $1,774 $220 $74–$782 $149
2023 $4,369 $208 $71–$635 $160
2024 $1,262 $237 $87–$681 $164
2025 $2,015 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. SeaPearl Inc $3,724 11 payments
  2. Stryker Corporation $2,836 32 payments
  3. Paragon 28, Inc. $1,582 6 payments
  4. Arthrex, Inc. $1,035 14 payments
  5. Integra LifeSciences Corporation $1,018 10 payments
  6. Kerecis Limited $702 7 payments
  7. Wright Medical Technology, Inc. $632 2 payments
  8. Genentech USA, Inc. $142 1 payment
  9. Organogenesis Inc. $138 2 payments
  10. Smith+Nephew, Inc. $70 4 payments
  11. Other $379 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,821 93 payments
  2. Travel and Lodging $4,340 12 payments
  3. Education $2,096 2 payments
Products named General payments · program years 2019–2025
  1. PRIMATRIX $956 7 payments
  2. INTEGRA DERMAL REGENERATION TEMPLATE $956 7 payments
  3. Integra Recon-Skin And Wound $937 6 payments
  4. Integra Recon-Skin And Wound $937 6 payments
  5. Integra Recon-Skin And Wound $937 6 payments
  6. MONKEY RINGS $708 1 payment
  7. PORTFOLIO $684 3 payments
  8. INFINITY Foot And Ankle $632 2 payments
  9. INFINITY Trauma & Extremities $630 9 payments
  10. Kerecis Omega3 SurgiClose $453 2 payments
  11. Other $7,844 115 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

286

Median for Podiatry: 160

Drug cost

$4,400

Median for Podiatry: $2,368

Branded share of claims

4.5%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Generic 39 $1,408
Ammonium Lactate Generic 58 $1,105
Ketoconazole Generic 36 $592
Diclofenac Sodium Generic 12 $502
Mupirocin Generic 23 $197
Methylprednisolone Generic 32 $182
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 13 $118
Meloxicam Generic 45 $108
Cephalexin Generic 13 $102
Ibuprofen Generic 15 $87

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$60,208

Of which drugs: $553

Medicare patients

218

Average age 74

Services billed

952

124 women, 94 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 39%
Ischemic heart disease 33%
Osteoporosis 24%
Chronic kidney disease 21%
Depression 21%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 30 99 $549

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record